Rhumbline Advisers Has $571.12 Million Stake in Johnson & Johnson (NYSE:JNJ)

Rhumbline Advisers trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,317,197 shares of the company’s stock after selling 60,100 shares during the quarter. Johnson & Johnson comprises 1.3% of Rhumbline Advisers’ investment portfolio, making the stock its 6th biggest holding. Rhumbline Advisers owned 0.16% of Johnson & Johnson worth $571,122,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. State Street Corp grew its holdings in shares of Johnson & Johnson by 4.3% during the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after purchasing an additional 6,656,371 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Johnson & Johnson by 4.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 11,623,639 shares of the company’s stock worth $1,537,692,000 after buying an additional 473,300 shares during the period. Fisher Asset Management LLC boosted its position in shares of Johnson & Johnson by 3.7% during the second quarter. Fisher Asset Management LLC now owns 11,499,415 shares of the company’s stock worth $1,521,258,000 after buying an additional 405,517 shares during the period. Clearbridge Investments LLC boosted its position in shares of Johnson & Johnson by 3.4% during the first quarter. Clearbridge Investments LLC now owns 9,543,827 shares of the company’s stock worth $1,188,684,000 after buying an additional 310,831 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Johnson & Johnson by 0.5% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,948,942 shares of the company’s stock worth $990,041,000 after buying an additional 42,144 shares during the period. 65.90% of the stock is owned by institutional investors.

Shares of Johnson & Johnson (JNJ) traded up $1.47 during mid-day trading on Wednesday, hitting $141.14. 958,413 shares of the company traded hands, compared to its average volume of 5,877,685. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The company has a market cap of $373,453.13, a P/E ratio of 19.47, a price-to-earnings-growth ratio of 2.83 and a beta of 0.80. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $144.35.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. During the same quarter in the previous year, the firm posted $1.68 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. equities research analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.38%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

JNJ has been the subject of a number of research analyst reports. Cowen restated an “outperform” rating and issued a $155.00 target price (up from $147.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. UBS reaffirmed a “buy” rating and issued a $148.00 price target on shares of Johnson & Johnson in a report on Thursday, August 31st. Jefferies Group upped their price target on Johnson & Johnson from $157.00 to $160.00 and gave the company a “buy” rating in a report on Monday, October 16th. Zacks Investment Research raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Finally, Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research note on Thursday, October 19th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company. Johnson & Johnson has an average rating of “Hold” and a consensus target price of $144.59.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://stocknewstimes.com/2017/12/06/rhumbline-advisers-sells-60100-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply